SARS-CoV-2 antibody after COVID-19 vaccination in patients with multiple sclerosis
Type of Study/Intervention
Prospective cohort study
Recruitment Status
Recruiting
Form of MS
Relapsing remitting MS, Secondary progressive MS, Primary progressive MS, Relapsing MS
Brief summary
COVID-19 vaccines are now being rolled out. Many people living with MS are treated with drugs that affect their immune system, and there is not a lot of specific data relating to the administration of the COVID-19 vaccines to a person with MS who is treated for their disease. This is a multi-center study to determine the COVID-19 vaccine immunogenicity and to assess the protection given by vaccines in people living with MS.
Inclusion criteria
– Diagnosed Multiple Sclerosis according to 2017 McDonald criteria
– Treatment by any TGA-approved Disease Modifying Therapy (DMT) for MS, e.g. ocrelizumab, alemtuzumab, natalizumab, fingolimod, cladribine, beta-interferon, copaxone, dimethylfumarate, ofatumumab, siponimod, glatiramer acetate.
– Recipient of COVID-19 vaccine (Pfizer, Astra Zeneca, or Novavax).
– Is able to give consent
Exclusion criteria
Non-English speaking
Anticipated start date
May 2021
Recruitment contacts
Fabienne Brilot-Turville, fabienne.brilot@sydney.edu.au
Region
NSW/VIC/QLD/WA
Ethics approval
Yes
Last updated
21/06/2021
